Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes

Ashrafian, 2007, Perhexiline, Cardiovasc. Drug Rev., 10.1111/j.1527-3466.2007.00006.x Ballatori, 2005, OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia, Hepatology, 42, 1270, 10.1002/hep.20961 Boelsterli, 2003, Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity, Toxicol. Appl. Pharmacol., 10.1016/S0041-008X(03)00368-5 Bohan, 2002, Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions, Semin. Liver Dis., 10.1055/s-2002-30099 Borges, 2005, Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy, Expert Opin. Drug Saf., 4, 69, 10.1517/14740338.4.1.69 Brackett, 2010, Clarifying metformin's role and risks in liver dysfunction, J. Am. Pharm. Assoc., 2003, 407, 10.1331/JAPhA.2010.08090 Bunchorntavakul, 2013, Acetaminophen-related hepatotoxicity, Clin. Liver Dis., 10.1016/j.cld.2013.07.005 Chatterjee, 2014, Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. Toxicol, In Vitro, 28, 218, 10.1016/j.tiv.2013.10.020 Chatterjee, 2014, Hepatocyte-based in vitro model for assessment of drug-induced cholestasis, Toxicol. Appl. Pharmacol., 274, 124, 10.1016/j.taap.2013.10.032 Chojkier, 2005, Troglitazone and liver injury: in search of answers, Hepatology, 10.1002/hep.20567 Dawson, 2012, In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans, Drug Metab. Dispos., 40, 130, 10.1124/dmd.111.040758 De Bruyn, 2013, Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity, Expert Opin. Drug Metab. Toxicol., 9, 589, 10.1517/17425255.2013.773973 Dhillon, 2009, Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension, Am. J. Cardiovasc. Drugs, 9, 331, 10.2165/11202270-000000000-00000 Maillette de BuyWenniger, 2010, Bile salts and cholestasis, Dig. Liver Dis., 10.1016/j.dld.2010.03.015 Dykens, 2007, The significance of mitochondrial toxicity testing in drug development, Drug Discov. Today, 12, 777, 10.1016/j.drudis.2007.07.013 Dykens, 2008, In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone, Toxicol. Sci., 103, 335, 10.1093/toxsci/kfn056 Fattinger, 2001, The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions, Clin. Pharmacol. Ther., 69, 223, 10.1067/mcp.2001.114667 Fischer, 1996, Hepatic levels of bile acids in end-stage chronic cholestatic liver disease, Clin. Chim. Acta, 251, 173, 10.1016/0009-8981(96)06305-X Fisher, 2002, Entacapone-induced hepatotoxicity and hepatic dysfunction, Mov. Disord., 17, 1362, 10.1002/mds.10342 Flaharty, 1989, Hepatotoxicity associated with amiodarone therapy., Pharmacotherapy, 10.1002/j.1875-9114.1989.tb04102.x Floyd, 2009, Case series of liver failure associated with rosiglitazone and pioglitazone, Pharmacoepidemiol. Drug Saf., 18, 1238, 10.1002/pds.1804 Francis, 2004, Ximelagatran: a new oral anticoagulant, Best Pract. Res. Clin. Haematol., 17, 139, 10.1016/j.beha.2004.03.005 Fromenty, 1995, Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity, Pharmacol. Ther., 67, 101, 10.1016/0163-7258(95)00012-6 Fukuda, 2013, Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity, Mol. Pharmacol., 84, 361, 10.1124/mol.113.086967 Funk, 2001, Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt, Toxicology, 167, 83, 10.1016/S0300-483X(01)00460-7 Gnewuch, 2009, Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease, World J. Gastroenterol., 15, 3134, 10.3748/wjg.15.3134 Kaplowitz, 2013 Keisu, 2010, Drug-induced liver injury in humans: the case of ximelagatran, Handb. Exp. Pharmacol., 196, 407, 10.1007/978-3-642-00663-0_13 Kenna, 2014, Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists, J. Pharmacol. Exp. Ther., 352, 281, 10.1124/jpet.114.220491 Kenne, 2008, Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol, In Vitro, 22, 730, 10.1016/j.tiv.2007.11.014 Kis, 2012, BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. Toxicol, In Vitro, 26, 1294, 10.1016/j.tiv.2011.11.002 Kleiner, 1997, Histopathologic changes associated with fialuridine hepatotoxicity, Mod. Pathol., 10, 192 Kock, 2013, Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters MRP3 and MRP4, Drug Metab. Dispos. Kostrubsky, 2006, Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone, Toxicol. Sci., 90, 451, 10.1093/toxsci/kfj095 Kubitz, 2012, The bile salt export pump (BSEP) in health and disease, Clin. Res. Hepatol. Gastroenterol., 36, 536, 10.1016/j.clinre.2012.06.006 Larson, 2007, Acetaminophen hepatotoxicity, Clin. Liver Dis., 10.1016/j.cld.2007.06.006 Lebovitz, 2002, Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction, Diabetes Care, 25, 815, 10.2337/diacare.25.5.815 Lee, 2003, Drug-induced hepatotoxicity, N. Engl. J. Med., 349, 474, 10.1056/NEJMra021844 Lee, 2005, Hepatic findings in long-term clinical trials of ximelagatran, Drug Saf., 28, 351, 10.2165/00002018-200528040-00006 Manning, 1995 Marion, 2007, Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity, Mol. Pharm., 10.1021/mp0700357 McGill, 2012, The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation, J. Clin. Invest., 122, 1574, 10.1172/JCI59755 McKenzie, 1995, Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B, New England J. Med., 10.1056/NEJM199510263331702 Miralles-Linares, 2012, Metformin-induced hepatotoxicity, Diabetes Care, 35, e21, 10.2337/dc11-2306 Morgan, 2010, Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development, Toxicol. Sci., 118, 485, 10.1093/toxsci/kfq269 Olanow, 2000, Tolcapone and hepatotoxic effects. Tasmar Advisory Panel., Arch. Neurol., 10.1001/archneur.57.2.263 Oorts, 2015, Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture, J. Pharmacol. Toxicol. Methods, 73, 63, 10.1016/j.vascn.2015.03.002 Padda, 2011, Drug-induced cholestasis, Hepatology, 53, 1377, 10.1002/hep.24229 Pauli-Magnus, 2006, Hepatobiliary transporters and drug-induced cholestasis, Hepatology, 44, 778, 10.1002/hep.21359 Pedersen, 2013, Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11), Toxicol. Sci., 136, 328, 10.1093/toxsci/kft197 Perez, 2009, Bile-acid-induced cell injury and protection, World J. Gastroenterol., 15, 1677, 10.3748/wjg.15.1677 Alrefai, 2007, Bile acid transporters: structure, function, regulation and pathophysiological implications, Pharm. Res., 24, 1803, 10.1007/s11095-007-9289-1 Rouru, 1999, Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition, Eur. J. Clin. Pharmacol., 55, 461, 10.1007/s002280050657 Scherer, 2009, Rapid quantification of bile acids and their conjugates in serum by liquid chromatography–tandem mass spectrometry, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 877, 3920, 10.1016/j.jchromb.2009.09.038 Sergent, 2009, Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol, In Vitro, 23, 1305, 10.1016/j.tiv.2009.07.019 Smith, 2003, Mechanisms of troglitazone hepatotoxicity, Chem. Res. Toxicol., 16, 679, 10.1021/tx034033e Unzueta, 2013, Nonsteroidal anti-inflammatory drug-induced hepatoxicity, Clin. Liver Dis., 10.1016/j.cld.2013.07.009 Van den Hof, 2014, Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro, BMC Syst. Biol. Submitted. Watkins, 2000, COMT inhibitors and liver toxicity, Neurology, 55, S51 Xiang, 2010, High performance liquid chromatography–tandem mass spectrometry for the determination of bile acid concentrations in human plasma, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 878, 51, 10.1016/j.jchromb.2009.11.019 Xu, 2008, Cellular imaging predictions of clinical drug-induced liver injury, Toxicol. Sci., 105, 97, 10.1093/toxsci/kfn109 Xu, 2014, fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing, PLoS Med., 11, 10.1371/journal.pmed.1001628 Yamazaki, 2013, Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats, Toxicol. Appl. Pharmacol., 268, 79, 10.1016/j.taap.2013.01.018 Yang, 2013, An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters, J. Pharm. Sci., 102, 3037, 10.1002/jps.23584 Yao, 2008, Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model, Br. J. Pharmacol., 154, 1446, 10.1038/bjp.2008.267 Yu, 2004, Selective sterol accumulation in ABCG5/ABCG8-deficient mice, J. Lipid Res., 45, 301, 10.1194/jlr.M300377-JLR200 Zhang, 2012, Compilation of 222 drugs' plasma protein binding data and guidance for study designs, Drug Discov. Today, 10.1016/j.drudis.2011.12.018